Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes

Diabetes Care

Volumn 33, Issue 10, 2010, Pages 2266-2270

  Krysiak, Robert ^a   Gdula Dymek, Anna ^a   Bachowski, Ryszard ^a   Okopién, Bogusław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BLOOD CLOTTING FACTOR 7; C REACTIVE PROTEIN; CYTOKINE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FIBRINOGEN; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ABSENCE OF SIDE EFFECTS; ARTICLE; BLOOD SAMPLING; CYTOKINE RELEASE; DIET RESTRICTION; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; METABOLIC RATE; METABOLIC SYNDROME X; MONOCYTE; PLEIOTROPY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; C-REACTIVE PROTEIN; CYTOKINES; FACTOR VII; FENOFIBRATE; FIBRINOGEN; HEPTANOIC ACIDS; HUMANS; METABOLIC SYNDROME X; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDIABETIC STATE; PYRROLES;

EID: 78649371385     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-0272     Document Type: Article

References (15)

1. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Pleiotropic effects of statins: clinical evidence. Curr Pharm Des 2009;15:479-489
2. Krysiak R, Okopień B, Herman Z. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 2003;63:1821-1854 (Pubitemid 37083030)
3. Keating GM, Ormrod D. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. Drugs 2002;62:1909-1944
4. Okopień B, Krysiak R, Kowalski J, Madej A, Belowski D, Zieliń ski M, Herman ZS. Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates. J Cardiovasc Pharmacol 2005;46:377-386 (Pubitemid 41262842)
5. Okopień B, Haberka M, Madej A, Belowski D, Labuzek K, Krysiak R, Zieliński M, Basiak M, Herman ZS. Extralipid effects of micronized fenofibrate in dyslipidemic patients. Pharmacol Rep 2006;58:729-735 (Pubitemid 44741692)
6. Okopień B, Krysiak R, Herman ZS. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab 2006;91:1770-1778
7. Pruski M, Krysiak R, Okopien B. Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. Diabetes Care 2009;32:1421-1424
8. Bulcão C, Ribeiro-Filho FF, Sañudo A, Roberta Ferreira SG. Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. Am J Cardiovasc Drugs 2007;7:219-224 (Pubitemid 47047989)
9. Okopien B, Krysiak R, Haberka M, Herman ZS. Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary mixed dyslipidemia. J Cardiovasc Pharmacol 2005;45:314-320 (Pubitemid 40411286)
10. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006;86:515-581
11. Kannel WB. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids 2005;40:1215-1220 (Pubitemid 43117845)
12. Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev 2007;65:S253-S259
13. Petersen JL, McGuire DK. Impaired glucose tolerance and impaired fasting glucose: a review of diagnosis, clinical implications and management. Diab Vasc Dis Res 2005;2:9-15 (Pubitemid 40333199)
14. Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack JR, Australian Diabetes Society, Australian Diabetes Educators Association. Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust 2007;186:461-465 (Pubitemid 46806823)
15. Milicevic Z, Raz I, Beattie SD, Campaigne BN, Sarwat S, Gromniak E, Kowalska I, Galic E, Tan M, Hanefeld M. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care 2008;(Suppl. 2):S155-S160